With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

Longer survival was seen in those with melanoma who received programmed cell death receptor-1 or its ligand who had a low neutrophil-lymphocyte ratio.

An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment ...

Vidutolimod and nivolumab demonstrated activity in a phase 2 trial of patients with high-risk, resectable melanoma.

The majority of patients had received prior PD-(L)1 based therapy. Encouraging signals of anti-cancer activity were observed ... 75-year-old patient with BRAF mutant metastatic cutaneous melanoma who ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...

"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients with metastatic melanoma who were refractory or resistant to PD-1 inhibitors. We are ...

Researchers reviewed 293 studies encompassing 305,879 adults with cancer who were treated with anti-CTLA4 or anti-PD-(L)1 therapy alone or in combination and had information available on ...